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Accepted 15 May 2019; Published online 20 May 2019AbstractObjective: The objective of this study was to provide insight into current practice in planning for, and acknowledging, the presence of
learning and clustering effects, by treating center and surgeon, when developing randomized surgical trials.
Study Design and Setting: Complexities associated with delivering surgical interventions, such as clustering effects, by center or sur-
geon, and surgical learning should be considered at trial design. Main trial publications, within the wider literature, under-report these con-
siderations. Funded applications, within a 4-year period, from a leading UK funding body were searched. Data were extracted on
considerations for learning and clustering effects and the driver, funder, or applicant, behind these.
Results: Fifty trials were eligible. Managing learning through establishing predefined center and surgeon credentials was common. One
planned exploratory analysis of learning within center, and two within surgeon. Clustering, by site and surgeon, was often managed through
stratifying randomization, with 81% and 60%, respectively, also planning to subsequently adjust analysis. One-third of responses to referees
contained funder led changes accounting for learning and/or clustering.
Conclusion: This review indicates that researchers do consider impact of learning and clustering, by center and surgeon, during trial
development. Furthermore, the funder is identified as a potential driver of considerations.  2019 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Randomized controlled trials (RCTs) are recognized as
providing the highest level of evidence, second only to sys-
tematic reviews of such trials [1]. The need for surgical ran-
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licenses/by-nc-nd/4.0/).push for growth in recent years [3,4]. Leading research or-
ganizations are supporting this growth through establishing
a number of initiatives and research objectives, ultimately
aiming to improve the global surgical evidence base
[5e10]. One such initiative, set up by the UK’s leading
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Key findings
 Results indicate that while considerations of surgical
learning and clustering are underreported in main trial
publications, funders and researchers alike appear to
be aware of the need to manage these aspects at trial
design stage.
What this adds to what is known?
 A novel assessment of the decision making behind in-
tended design and analysiswith respect to themanage-
ment of surgical learning and clustering is presented.
 This review investigates successful funding appli-
cations comprising a wide variety of trials, both
by surgical discipline and by geographic location,
by a leading UK funder.
 This review is timely as it comprises successful
funding applications following a call by this funder
recognizing a need for an increase in evidence-
based surgical research.
What is the implication and what should change
now?
 Insight into the promising role of the funder as a
driver to improving the, long criticized, surgical
evidence base is provided.
for Health Research (NIHR), aimed to increase the volume
of high-quality research, across surgical disciplines, on the
effectiveness, delivery, and organization of surgery and sur-
gical services [7]. More recently, the NIHR Unit on Global
Surgery was formed [10], to establish research hubs in low-
and middle-income countries across the world. With the
conduct of surgical trials growing in number, and becoming
more geographically dispersed, ensuring that they are de-
signed and analyzed appropriately is essential to support
clinical decision making.
The assessment of surgical interventions is complex,
because of the interacting components, such as the inter-
vention itself, surgical expertise, and preoperative and post-
operative care [11]. When designing randomized surgical
trials, it is important to consider the potential existence
and impact of surgical learning curves, where the surgical
expertise increases throughout the course of the trial.
Another important consideration is clustering. Clustering
occurs when patient outcomes within center, surgical team,
or surgeon are more similar than those from patients treated
by different centers, teams, or surgeons.
Recognition and management of learning curves and
clustering within clinical trials is recommended, [12] and
may have increased relevance within the surgical field,
E.J. Conroy et al. / Journal of Clidependent upon the interventions being investigated and
their routine use [11e15].
It is important to consider the significance of these as-
pects at trial outset, to ensure that the resulting trial is con-
ducted and analyzed with the highest possible rigor.
However, main trial publications often do not report delib-
erations and justifications for selected approaches [16]. To
overcome this limitation, we investigate a cohort of appli-
cations for randomized surgical trials funded by the NIHR.
This review will determine how learning and clustering, by
center and surgeon, are managed at the design stage and ac-
counted for in the intended analysis, and provide insight
into who drives the decision making for these: the funder,
guided by reviewers and panel members, or the researcher.
We aim to provide a more detailed insight into current prac-
tice with regards to planning for, and acknowledging, the
presence of learning and clustering when designing ran-
domized surgical trials.2. Materials and methods
2.1. Included studies
We sought to examine trials that had received funding
from the NIHR from two funding streams, the Health Tech-
nology Assessment (HTA) program [17] and Efficacy and
Mechanism Evaluation (EME) [18] program, in the United
Kingdom, from 2012 to 2016. Research projects funded by
these programs are either in response to a commissioning
brief or an open investigator-led call. These funding
streams were chosen as they are known to endorse high-
quality research and were actively funding surgical research
during this time [7]. An initial unpublished search indicated
that this period would provide a reasonable cohort size to
establish current practice. All randomized trials where the
patient pathway involves a surgical intervention of any kind
were eligible for inclusion.
2.2. Documents for review
The NIHR HTA and NIHR EME funding process in-
volves a two-stage, peer-reviewed application process. Pro-
tocols and the commissioning brief (where applicable) were
obtained from the open-access NIHR Journals Library [19].
The NIHR Evaluation, Trials and Studies Coordinating
Centre (NETSCC) provided documentation not publicly
available: project descriptions and applicant responses to
reviewer comments.
2.3. Data extraction
A previously developed extraction form [16] was adapt-
ed for use on this cohort by E.J.C. and C.G. and approved
by G.B., J.M.B., and J.A.C. (see Supplement A1). The
extraction form was piloted on five applications initially
and, as no further amendments were required, subsequently
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extracted were quality-checked through double data extrac-
tion by a second reviewer (A.R.H.) on 10% of all applica-
tions. A discrepancy rate was specified a priori such that if
greater than 5% across all fields then a further 10% would
be checked until the rate was below 5%. Discrepancies
were jointly reviewed and agreement was reached; if agree-
ment could not be reached, then a third reviewer (C.G.) was
consulted.
Details on trial design, randomization stratification, sam-
ple size adjustment, predetermined center and surgeon cre-
dentials, outcomes, and planned statistical analyses that
adjusted for center and surgeon were collected.
2.4. Statistical analysis
Quantitative items were summarized using descriptive
statistics; no formal statistical comparisons were under-
taken. Data were analyzed using SAS 9.3 (SAS Institute
Inc., Cary, NC, USA). Open textual data items were catego-
rized using NVivo qualitative data analysis software (QSR
International Pty Ltd., Doncaster, Victoria, Australia,
version 10, 2012). A confidentiality agreement with the
NIHR Evaluation, Trials and Studies Coordinating Centre
was signed prior to receiving the documentation. The raw
data cannot therefore be made publicly available, and text
extracts have been anonymized by removal of treatment
or condition identifiers. Deleted text is denoted by [.]
and the addition of words or replaced words is denoted
by [words] to aid understanding.3. Results
3.1. Cohort details
The NETSCC compiled a report listing all surgery ran-
domized controlled trials funded by the NIHR HTA and
NIHR EME funding streams within the eligible period.
Sixty potentially eligible studies were identified, of which
49 (82%) met the eligibility criteria following further cen-
tral screening (Fig. A1).
3.2. Double data extraction
Five articles were randomly selected from the eligible
studies for double data extraction. Of 155 variables
checked, two discrepancies were identified (1% error rate).
3.3. Cohort summary
The majority of the applications were funded by the
NIHR HTA (n 5 44/49, 89%) and had start dates from
2014 onward (n 5 37/49, 76%) (see Table 1).
Documents for review consisted of commissioning
briefs (n 5 15/49, 31%), project descriptions (n 5 40/49,
82%), applicant responses to board and peer review com-
ments (n 5 40/49, 82%) and protocols (n 5 42/49, 86%).Either the protocol or project description was available
for all applications (see Table 1).
One application consisted of two distinct RCTs, herein
treated as two separate trials.3.4. Trial demographics
Trials were primarily two-armed (n 5 45/50, 90%) and
of a parallel design (n 5 49/50, 98%). Eight did not use a
pilot or feasibility study (n 5 8/50, 16%) [20]. In 11 studies
(n5 11/50, 22%), surgery was not the intervention of inter-
est and delivered as part of the patient pathway. Where sur-
gery was the intervention of interest (n 5 39/50, 78%), 21
compared against surgery, for example, minimal access vs.
open surgery (n 5 21/39, 54%). The remaining 18
compared surgery against a nonsurgical comparator (medi-
cal comparator, e.g., injection vs. surgery: n 5 7/39, other
e.g., active monitoring and surgery vs. active monitoring
only: n 5 11/39) (see Tables A1 and 2).3.5. Recruitment and randomization
Patients were the randomization unit in all trials and
were primarily allocated to equal groups (n 5 48/50,
96%). The majority stratified randomization (n 5 46/50,
92%). In trials comparing two surgeries, there were no
expertise-based designs [21]. Table A2 provides more
detail.
Almost all studies were multicentere (n 5 49/50, 98%),
with over half stratifying by center (n 5 28/49, 57%).
Of the 21 that did not stratify by center, one
provided justification for not stratifying by centre and this
was related to concern over allocation concealment:‘‘To reduce the risk of the randomization sequence
being predictable we will not stratify by center, which
in addition to using randomly selected permuted
blocks, will make the allocation sequence unpredict-
able for individual trial centers.’’Twenty-two trials had multiple surgeons within each
center, of which eight stratified the randomization accord-
ingly (n 5 8/22, 36%). Two surgeon-stratified trials fol-
lowed funder recommendation.‘‘We have made a number of changes since the first
application.randomization will be stratified accord-
ing to [stratification 1], [stratification 2], and accord-
ing to consultant surgeon.’’In trials reported as multicenter and multisurgeon
(n 5 21), two stratified for both center and surgeon, eleven
center only, six surgeon only, and two stratified for neither.
Three trials were international, of which one stratified
randomization on randomized within a UK, or non-UK,
center.
Table 2 provides more detail.
Table 1. Cohort summary
Item Category n N n/N%
Number of RCTs in application One 48 49 98%
Two 1 49 2%
Funder NIHR HTA 44 49 90%
NIHR EME 5 49 10%
Lead institution region East 1 49 2%
East Midlands 4 49 8%
London 10 49 20%
North East 7 49 14%
North West 2 49 4%
Scotland 10 49 20%
South East 3 49 6%
South West 4 49 8%
Wales 2 49 4%
West Midlands 4 49 8%
Yorkshire and the Humber 2 49 4%
Trial start year 2012 3 49 6%
2013 9 49 18%
2014 26 49 53%
2015 3 49 6%
2016 1 49 2%
2017 7 49 14%
Source documents availablea Commissioning brief 15 49 31%
Project description 40 49 82%
Responses to board and peer
review comments
40 49 82%
Protocol 42 49 86%
Abbreviations: EME, Efficacy and Mechanism Evaluation; HTA, Health Technology Assessment; NIHR, National Institute for Health Research;
RCTs, randomized controlled trials.
a Documents available: All applications with project description also had responses to board and peer review comments (n 5 40). A minimum
of either the protocol or the project description and responses to board and peer review comments were available for all applications.
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Center and surgeon credentials, or inclusion criteria of
those delivering the intervention, were provided in 41Table 2. Stratification factors in multicenter and multisurgeon trials by inte
Nature of surgery
delivered Comparator
Number of
trials in
cohort
Mu
As an intervention Surgery Alternative surgical
procedure
13
Change to a component of
the same procedure
6
Same procedure delivered
at a different time point
2
Medical 7
Other 11
As part of patient pathway 11(n 5 41/50, 82%) and 36 (n 5 36/50, 72%) trials respec-
tively (Table 3). Most common center credentials were case
volume (n 5 20) and required fields of expertise within
center (n 5 13). Examples of surgeon credentials werervention type
Stratified by center Stratified by surgeon
lticenter Yes No Multisurgeon Yes No
N n n/N% n n/N% N n n/N% n n/N%
13 5 38% 8 62% 6 4 67% 2 33%
5 4 80% 1 20% 6 3 50% 3 50%
2 1 50% 1 50% 0 0 e 0 e
7 5 71% 2 29% 2 0 e 2 100%
11 5 45% 6 55% 3 0 e 3 100%
11 8 73% 3 27% 5 1 20% 4 80%
Table 3. Center and surgeon credentials
Center level Surgeon level
Center credential provided 41 Surgeon credentials provided 36
Case volume 20 (48%) Level of job role 16 (44%)
Fields of expertise within center 13 (32%) Study-specific training 13 (36%)
Experience required without definition 9 (22%) Experience required without definition 8 (22%)
Experience required with definition 8 (20%) Oversight of supervision 7 (19%)
Good recruiting reputation 8 (20%) Prior number of cases 7 (19%)
Experience required with definition 8 (20%) Self-assessed ability 7 (19%)
Access to equipment required 7 (17%) Equipoise 4 (11%)
Center to undertake trial-specific
training
2 (5%) Known to be good recruiters 3 (8%)
Demonstrated ability to participate 1 (2%) Case volume 2 (6%)
Interest expressed in specific treatment 1 (2%) Local practice relevant 1 (3%)
Prior number of cases required 1 (2%)
Center delivers one treatment only 1 (2%)
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(n 5 13).
3.7. Trial outcomes related to learning and clustering
Forty-one applications explored outcomes that may
reflect variability in center or surgeon skill (82%,
Table 4). Common outcomes were safety events
(n 5 36); recovery from surgery (n 5 13), and operative
time (n 5 6).
Surgeon level outcomes were experience of surgeons in
trial, established through qualitative methods (n 5 3); sur-
geon accuracy as a main trial outcome (n 5 1); and exper-
tise (n 5 1), more specifically:Table 4
Outcom
Releva
Safe
Rec
Ope
Pati
Infe
Expe
Surg
Surg
a E
b F‘‘The first [feasibility] phase will establish [words]
and a measure of surgical expertise.’’3.8. Statistical considerations
3.8.1. Sample size calculation
There were no examples of sample size adjustment for
clustering at a center level. Three applications adjusted. Outcomes
e
nt outcome reported 41
ty measures 36 (88%)
overy from surgery time 13 (32%)
rative time 6 (15%)
ent satisfaction with surgery 5 (12%)
ction 4 (10%)
rience of surgeons in triala 3 (7%)
eon accuracy 1 (2%)
eon expertiseb 1 (2%)
stablished using qualitative methods.
easibility outcome.the sample size for surgeon using an intraclass correlation
coefficient and a fourth chose not to adjust although pro-
vided justification:‘‘As this study is not evaluating surgery per-se, surgi-
cal experience is not a criterion for participation (all
participants will be under the care of a consultant
surgeon). In the context of [this] study, clustering
by surgeon is not relevant to the sample size and
can be ignored (on the basis that the intraclass
correction is negligible).’’3.8.2. Exploratory analysis
Eight applications planned exploratory analysis consid-
ering differences by center. Three analyzed using descrip-
tive statistics and three via a subgroup analysis: the first
conducting a trial center-by-treatment effect analysis, the
second comparing outcomes between more and less experi-
enced centers, and the third exploring trends within centers
over time. A sensitivity analysis adjusting for center effects
was planned in one application. Learning within center was
described in another.‘‘The effect of experience in [comparator interven-
tion] at each recruitment center will be studied to
characterise the effect of the learning curve on clin-
ical effectiveness, and also the effect on [standard
intervention] outcomes.’’Exploratory analyses considering differences by surgeon
were planned in seven applications, of which three also
explored by center. Two analyzed descriptively by surgeon
grade and four via subgroup analysis: one modeled the
learning curve using outcomes operation time and compli-
cations as a proxy to measure the task efficiency of the sur-
geon, one planned to explore trends and changes over time
between experienced and less experienced surgeons, one
via a qualitative analysis, and the final where patients were
Table 5. Planned statistical adjustments through analysis in multicenter and multisurgeon trials
Center Surgeon
n N n/N% n N n/N%
Adjustment made 21 49 43% 15 22 68%
Approach to adjustment (type of effect)
Fixed 0 21 e 0 15 e
Random 9 21 43% 6 15 40%
Time varying 0 21 e 0 15 e
Not specified 12 21 57% 9 15 60%
Randomization stratified by and
adjustment made
Yes 17 21 81% 9 15 60%
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ing surgeons’ grade. As with center, one application
planned a sensitivity analysis that adjusted for surgeon.
3.8.3. Formal adjustment
Formal adjustment for multiple center or surgeon effect
was planned in 21 and 15 applications, respectively. Table 5
provides more detail. When formally adjusting for center,
nine planned to use a random effect and thirteen did not
specify. Similarly, six planned to adjust for surgeon using
a random effect and nine did not specify. Of the applica-
tions planning a formal adjustment, 17 (n 5 17/21, 81%)
of applications adjusting for center and nine (n 5 9/15,
60%) adjusting for surgeon did so in addition to stratifying
randomization by these variables.
The two applications that planned to stratify by both
center and surgeon (Table 3) also planned formally adjust-
ing analysis by these factors.
3.9. Funder-led considerations
3.9.1. Commissioning briefs
Of the 15 commissioning briefs, one permitted single-
center studies and one required a multicenter setting. No
other brief gave guidance with respect to number of cen-
ters. Two briefs identified surgical learning consider-
ations as an issue to address: the first indicating
outcomes may be independent of surgeon grade and the
second:‘‘Proposals should account for the possibility of a
learning curve affecting the outcomes of [surgery].’’3.9.2. Changes driven by funder
Response to referee comments were available for 40
studies (n 5 40/49, 82%). Fourteen examples of change
within 12 applications were identified. Funder concerns
led to sample size adjustment for surgeon (n 5 3); random-
ization balanced for surgeon (n 5 2) and center (n 5 1);
and improved generalizability by increasing the number
of centers (n 5 3):‘‘The Board suggested that the team should consider
the addition of a second center to demonstrate gener-
alisability and help with recruitment.’’In one application, funders requested applicants increase
homogeneity in treatments and the applicants argued
against this.‘‘To ensure homogeneity in treatments we have con-
sulted with our participating surgeons [and] the Na-
tional [.] Registry and agreed to specify the use of a
CE marked [device.there are three main devices].
Surgical trials that specify a single type of [device]
are notoriously difficult to conduct and we do not
believe such a design could recruit surgeons, nor
would the outputs be generalisable.’’Further considerations with regard to surgeon creden-
tials (n5 3) and the impact of surgeon equipoise on recruit-
ment (n 5 1) were also funder driven.‘‘The sample size has been increased from a total of
[n] patients to a total of [1.4n] to take into account
clustering of surgeon as per the feedback from the
first stage.’’4. Conclusions
This review has investigated the decision making behind
intended design and analysis of 50 randomized surgical tri-
als funded by the NIHR EME and NIHR HTA programs
from 2012 to 2016. These results show frequent consider-
ation of centers and surgeon impact during design, and
these may be funder led, due to concerns around homoge-
neity or generalizability of results. This review provides a
cross-sectional insight into current practice of researchers,
and expectations of reviewers and funders, during trial
design within two streams of a major UK funder [17,18].
The need for transparency around learning curves and
clustering is highlighted within reporting of nonpharmaco-
logical interventions guidelines [22,23], and a review of the
published literature identified a deficiency in adherence to
these [16]. By contrast, this review identifies that
34 E.J. Conroy et al. / Journal of Clinical Epidemiology 113 (2019) 28e35considerations to manage learning and clustering are made,
by both researchers and funders, during development of tri-
als funded by a prestigious body. For example, 30% of
multicenter and 12% of multisurgeon studies reported a sta-
tistical adjustment of these within published manuscripts.
This was 43% and 68%, respectively, in this cohort. When
randomization was stratified by center or surgeon, this was
accounted for in the analysis in 30% of multicenter and
40% of multisurgeon trials in the published manuscripts,
as opposed to 81% and 60% in this cohort. In drawing
this comparison, it is important to differentiate between
the intended audiences. The detail required for a funding
application, assessed by clinicians and methodologists/
statisticians, may exceed that required to communicate re-
sults to a clinical audience. This demonstrates benefit in
exploring unpublished trial documentation to understand
approaches to trial design and analysis and highlights the
need for improvements to transparent reporting.
The cohort included successful applications to the NIHR
2012 call for Applied Health in Surgery [7]. This call recog-
nized the need to increase research-based evidence in
surgery. Applications that evaluated technology-driven
implanted or implantable medical devices, surgical proced-
ures, or surgical services were invited. As a clinical trial is
typically a major financial investment [24], applicants need
to assure funders that their proposal is important, is well
designed, and demonstrates scientific value to add to the
current evidence base. Each application undergoes a peer
review process, where ‘‘experts’’ critically review the trial
to ensure standards are met in terms of design, quality,
feasibility, acceptability, and importance of the topic
[17,18]. A strength of this review is the insight into the
designs proposed to funders, and impact of feedback on
subsequently funded studies.
While the degree of learning and clustering will vary trial-
to-trial, many interventions require surgical skill in their de-
livery regardless of whether the surgery is the intervention of
interest. The impact of any potential imbalance in delivery
on comparing interventions should be considered at trial
outset routinely. Early and careful consideration will ensure
that procedures are standardized as completely as possible
such that, in severe cases, the trial team can alleviate any
doubts about homogeneity raised by the medical community
should the trial results be questioned [12]. These results indi-
cate funder awareness of this early consideration, with one of
the two examples of balancing randomization surgeon
following recommendation being in a trial where surgery
was not the intervention of interest.
When interpreting these results, it is important to
consider the limitations of this review. First, only successful
applications could be included because of confidentiality
constraints. It is therefore not possible to determine whether
the management of learning and clustering contributes to
the success of the application. However, given that the
application process consists of iterations whereby peer re-
viewers are able to request that researchers addresspaucities in their application, it is unlikely that a promising
application, lacking in the appropriate considerations,
would be deemed unsuitable for funding outright. More
likely, researchers would be given the opportunity to make
these considerations during this iteration process. Second,
as part of this iterative review, it is possible that additional
discussions at the funder board meetings did not make it in
to the comments fed back to applicants. This could mean
that funders raised these issues more frequently than this re-
view suggests. Third, due to the nature of the grant applica-
tion process, the funder impact observed may be in part due
to an increased awareness of the reviewers involved.
Fourth, this work has focused on a single funding body that
primarily supports UK-based research. However, trials sup-
ported span a wide range of surgical specialties and health
care conditions and results from this review will be gener-
alizable to other funding bodies with a similar peer review
process.
Fundamental to trial design and analysis is understand-
ing the objectives. While considerations relating to clus-
tering and learning effects are not widely reported in
main trial publications, these results indicate both funders
and researchers consider these aspects to address a specific
research question. Such issues may have varying relevance
depending on the overall design of the trial. A very prag-
matic study may deliberately include surgeons and centers
of all types and have less emphasis on expertise and
learning, whereas the delivery of the intervention in more
explanatory studies is critical and requires consideration
during design and analysis. Another approach to over-
coming these issues is to provide quality assurance of the
intervention. Early work to develop methods to achieve this
have been developed, and it is expected that this will
expand in the future [25]. Furthermore, these results pro-
vide insight into the promising role of the funder as a driver
to improving the, long criticized, surgical evidence base.
The funder, who has influence over whether and how
studies are carried out and has been suggested as a driver
for improving the quality of research during the period of
growth for surgical trials [3], can play a valuable role in
ensuring that future trials do not have the same shortfalls
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